About 100 reports

  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Companies in China

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • Eisai Co., Ltd.
  • Novartis AG
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Sales Volume

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • Demand
  • Eisai Co., Ltd.
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Other Blood Disease Drugs
  • Blood Disease Drugs Imports

In 2007, Inosine import contribution to Blood Disease Drugs was ##. ##% while the figure was ##% in 2012 and ##. ##% in 2017.

  • Blood Disease
  • Market Shares
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Medical & surgical hospitals nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Offices of physicians nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand

AFTER DONATION, EACH UNIT OF DONATED BLOOD IS REQUIRED TO UNDERGO A SERIES OF TESTS FOR INFECTIOUS DISEASES, INCLUDING: ##.

  • Blood Disease
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

POLYCYTHEMIA VERA IS A RARE BLOOD DISEASE CHARACTERIZED BY AN INCREASED NUMBER OF RED BLOOD CELLS, WHITE BLOOD CELLS AND PLATELETS, WHICH SIGNIFICANTLY RAISES THE RISK FOR THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

May ##, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases Rivella and colleagues published their study online today in the journal Blood.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.

May ##, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases Rivella and colleagues published their study online today in the journal Blood.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Global Acquired Orphan Blood Diseases Therapeutics Market
  • Global Acquired Orphan Blood Diseases Therapeutics Market

Patients can be affected with any one of the acquired orphan blood diseases.

  • Blood Disease
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile

In beta-thalassemia, a long-studied genetic disorder, a mutation impairs hemoglobin production, resulting in defective red blood cells (RBCs).

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Additional Areas in Sickle Cell Disease Date and Time: Thursday, October ##, 2017, ##:##-##:## p. m.

  • Blood Disease
  • Therapy
  • World
  • Company Operations
  • Roche Group
  • BIOMARKER ASSAY - SEPSIS - PRODUCT DESCRIPTION

Liquid biopsy: Detection of cancer or other diseases by testing bodily fluids such as blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • Medical Device
  • Grifols, S.A.
  • DIAGNOSTIC TEST - HEMOPHILIA - PRODUCT DESCRIPTION
  • SPINIT DEVICE - THROMBOCYTOPENIA ASSAY - PRODUCT DESCRIPTION

From ## of these players, blood samples were taken ##, ##, ## and ## hours (six days) after the concussion.

  • Blood Disease
  • Drug Development
  • In Vitro Diagnostic Reagent
  • Point Of Care Testing
  • Siemens Healthcare GmbH
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Shire plc

PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs).

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • Dec 04, 2017: La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC-401 in Patients With Beta Thalassemia
  • SMALL MOLECULES TO INHIBIT PRMT5 FOR SICKLE CELL DISEASE, THALASSEMIA AND SOLID TUMOURS - DRUG PROFILE

VCN in peripheral blood was ##. ##copies/ genome at ## month after LentiGlobin infusion.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • Clinical Trials

Enrollment and treatment are ongoing in Part ## of the Phase ## trial in patients with CMT disease.

  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Acceleron Pharma, Inc.

Sickle cell disease is a debilitating genetic disorder that causes red blood cells to become sickle-shaped, reducing normal red blood cell number, blood flow and oxygen delivery to organs.

  • Blood Disease
  • Hospital
  • Pharmaceutical
  • Therapy
  • NicOx S.A.
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

The organization is developing medicines for rare neuromuscular diseases, liver diseases, blood and eye disorders.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • Featured News & Press Releases

An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a s

  • Blood Disease
  • Japan
  • United States
  • Product Initiative
  • Ablynx NV
  • JUL 09, 2018: CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III 'BELIEVE' STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA

ACE-## is currently being evaluated in two Phase ## trials: one in FSHD and one in Charcot-Marie-Tooth (CMT) disease.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.

As of 2013, THERE ARE NO BIOSIMILARS AVAILABLE TO TREAT BLOOD DISORDERS AND INFECTIOUS DISEASES.

  • Biosimilar
  • Blood Disease
  • Forecast
  • Market Size
  • Sandoz Inc.
  • Market challenges

Males are susceptible to this disease as they have only one X chromosome.

  • Blood Disease
  • World
  • Market Size
  • Biogen Idec Inc.
  • CSL Behring GmbH

BY SEX, 2012 (NO. ) ## Hodgkin Lymphoma in the United Kingdom ## TABLE ## ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U. K., 2013 (NO. ) ## TABLE ## ESTIMATED NUMBER OF DEATHS FROM HODGKIN' S LYMPHOMA IN THE U. K., 2012 (NO. ) ## FIGURE ## ESTIMATED NUMBE

  • Blood Disease
  • Cancer
  • Pathology
  • United States
  • World
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

The organization is developing medicines for rare neuromuscular diseases, liver diseases, blood and eye disorders.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
  • pharmacodynamics of PRM-151 administered intravenously to patients with IPF.

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • Vaccine
  • United States
  • Merck & Co., Inc.
  • MEXICO: APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • GLOBAL THERAPEUTIC APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021, (USD MILLION)

S. ##. ##. ##. ## The FDA approves apheresis blood collection devices intended for the collection of certain blood components only.

  • Blood Disease
  • North America
  • United States
  • World
  • Market Size

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Blood Disease
  • Leukemia
  • Therapy
  • World
  • Product Initiative
  • SPINIT DEVICE - THROMBOCYTOPENIA ASSAY - PRODUCT DESCRIPTION

PT/ ##:## p. m.

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • In Vitro Diagnostic Reagent
  • Helena Laboratories Corporation